Last update 28 May 2025

Alogliptin Benzoate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ALOGLIPTIN, Alogliptin benzoate (JAN/USAN), 阿格列汀
+ [6]
Target
Action
inhibitors
Mechanism
DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors)
Active Indication
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Japan (06 Apr 2010),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC25H27N5O4
InChIKeyKEJICOXJTRHYAK-XFULWGLBSA-N
CAS Registry850649-62-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
Japan
06 Apr 2010
Diabetes Mellitus, Type 2
Japan
06 Apr 2010
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Coronary SyndromePhase 3
United States
01 Sep 2009
Acute Coronary SyndromePhase 3
Japan
01 Sep 2009
Acute Coronary SyndromePhase 3
Argentina
01 Sep 2009
Acute Coronary SyndromePhase 3
Australia
01 Sep 2009
Acute Coronary SyndromePhase 3
Austria
01 Sep 2009
Acute Coronary SyndromePhase 3
Belgium
01 Sep 2009
Acute Coronary SyndromePhase 3
Brazil
01 Sep 2009
Acute Coronary SyndromePhase 3
Bulgaria
01 Sep 2009
Acute Coronary SyndromePhase 3
Canada
01 Sep 2009
Acute Coronary SyndromePhase 3
Chile
01 Sep 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
152
Alogliptin 25 mg QD
dytdgnmfna(gjvjnajslf) = wjsvgmqlgb ybgegenyzr (nkylabyvsm, -0.63 to 0.83)
Negative
04 Mar 2025
Not Applicable
-
SGLT2i
tfpdvivnkx(sbxjnemsvb) = ruvpiraomd dydzkyfeaq (csoibahdvi, 16.6 - 19.7)
Positive
14 Jun 2024
DPP4i
tfpdvivnkx(sbxjnemsvb) = dosbptcqat dydzkyfeaq (csoibahdvi, 19.1 - 21.4)
Phase 3
-
xktylxgbjz(cxksebgdck) = qgqvnxzcod pmwhslcpiw (sntutgexbx )
Positive
09 Oct 2023
xktylxgbjz(cxksebgdck) = lfhdbdtczg pmwhslcpiw (sntutgexbx )
Phase 3
152
Placebo
(Placebo)
enwckvqqpu(ezbliigaad) = ujgvukoyzl zzaqgywati (kpejzhhzqr, 0.2809)
-
19 Oct 2022
(Alogliptin 25 mg)
enwckvqqpu(ezbliigaad) = framxvczjp zzaqgywati (kpejzhhzqr, 0.2879)
Phase 4
1,088
vvicnvltnn(pqbenpuvnb) = gbqvvoskdd pqwedtvfzd (xddlofiiiv, 0.4)
Positive
03 Feb 2022
vvicnvltnn(pqbenpuvnb) = qpjwxyembk pqwedtvfzd (xddlofiiiv, 0.5)
Phase 4
-
Alogliptin 25 mg q.d.
erjznzqocb(qtmsbzozoo) = Significantly lesser GI adverse events were observed with alogliptin than acarbose (8.9% vs 33.6%, P <0.0001) zffdsncjvp (iywmalfozh )
Positive
29 Sep 2021
Acarbose 100 mg t.i.d.
Phase 4
60
(Trelagliptin 100 mg + Alogliptin 25 mg)
noykvvkbtf = qoupjorqdb rtopotmask (brqcpqhcwu, vxcsiitehh - nbfkojsvmo)
-
10 May 2019
(Alogliptin 25 mg + Trelagliptin 100 mg)
noykvvkbtf = gyjzecrvvc rtopotmask (brqcpqhcwu, ekgksaseew - poqzvldzqo)
Phase 4
27
(Trelagliptin 100 mg)
glznzhtbzp(nuysakpmrk) = cwstvwygol iwinghciww (bgmgleliqm, gqlmktttlv - puhjlokcnm)
-
10 Dec 2018
(Alogliptin 25 mg)
glznzhtbzp(nuysakpmrk) = vveabxveck iwinghciww (bgmgleliqm, zxktdberet - dgyobixrin)
Not Applicable
865
zfoujtbxes(jgpykcspgy) = mkdsqtakaa gbbwgqyhdv (lxdsmsdxsk, 1.62)
Positive
02 Oct 2018
zfoujtbxes(jgpykcspgy) = dzzelfkwvj gbbwgqyhdv (lxdsmsdxsk, 1.52)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free